Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 0.34
AMEX:HLTH's Cash-to-Debt is ranked lower than
54% of the 259 Companies
in the Global Medical Care industry.

( Industry Median: 0.48 vs. AMEX:HLTH: 0.34 )
Ranked among companies with meaningful Cash-to-Debt only.
AMEX:HLTH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 3.65 Max: No Debt
Current: 0.34
Equity-to-Asset 0.46
AMEX:HLTH's Equity-to-Asset is ranked lower than
53% of the 255 Companies
in the Global Medical Care industry.

( Industry Median: 0.48 vs. AMEX:HLTH: 0.46 )
Ranked among companies with meaningful Equity-to-Asset only.
AMEX:HLTH' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.73  Med: 0.4 Max: 0.81
Current: 0.46
-0.73
0.81
Interest Coverage 3.63
AMEX:HLTH's Interest Coverage is ranked lower than
73% of the 216 Companies
in the Global Medical Care industry.

( Industry Median: 8.41 vs. AMEX:HLTH: 3.63 )
Ranked among companies with meaningful Interest Coverage only.
AMEX:HLTH' s Interest Coverage Range Over the Past 10 Years
Min: 2.51  Med: N/A Max: No Debt
Current: 3.63
Piotroski F-Score: 4
Altman Z-Score: 1.66
Beneish M-Score: -2.44
WACC vs ROIC
2.01%
6.33%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 5.48
AMEX:HLTH's Operating Margin % is ranked lower than
58% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 7.34 vs. AMEX:HLTH: 5.48 )
Ranked among companies with meaningful Operating Margin % only.
AMEX:HLTH' s Operating Margin % Range Over the Past 10 Years
Min: -13.69  Med: 14.3 Max: 64.77
Current: 5.48
-13.69
64.77
Net Margin % 2.98
AMEX:HLTH's Net Margin % is ranked lower than
60% of the 261 Companies
in the Global Medical Care industry.

( Industry Median: 4.40 vs. AMEX:HLTH: 2.98 )
Ranked among companies with meaningful Net Margin % only.
AMEX:HLTH' s Net Margin % Range Over the Past 10 Years
Min: -243.59  Med: 2.85 Max: 22.18
Current: 2.98
-243.59
22.18
ROE % 6.72
AMEX:HLTH's ROE % is ranked lower than
62% of the 243 Companies
in the Global Medical Care industry.

( Industry Median: 9.35 vs. AMEX:HLTH: 6.72 )
Ranked among companies with meaningful ROE % only.
AMEX:HLTH' s ROE % Range Over the Past 10 Years
Min: -141.14  Med: -3.11 Max: 61.25
Current: 6.72
-141.14
61.25
ROA % 3.43
AMEX:HLTH's ROA % is ranked lower than
53% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 3.85 vs. AMEX:HLTH: 3.43 )
Ranked among companies with meaningful ROA % only.
AMEX:HLTH' s ROA % Range Over the Past 10 Years
Min: -96.85  Med: 2.79 Max: 29.27
Current: 3.43
-96.85
29.27
ROC (Joel Greenblatt) % 22.68
AMEX:HLTH's ROC (Joel Greenblatt) % is ranked higher than
58% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 16.07 vs. AMEX:HLTH: 22.68 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AMEX:HLTH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -61.1  Med: 73.21 Max: 269.5
Current: 22.68
-61.1
269.5
3-Year Revenue Growth Rate 63.90
AMEX:HLTH's 3-Year Revenue Growth Rate is ranked higher than
99% of the 193 Companies
in the Global Medical Care industry.

( Industry Median: 8.00 vs. AMEX:HLTH: 63.90 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
AMEX:HLTH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -48.5  Med: -6.95 Max: 205.5
Current: 63.9
-48.5
205.5
3-Year EBITDA Growth Rate 13.40
AMEX:HLTH's 3-Year EBITDA Growth Rate is ranked higher than
65% of the 167 Companies
in the Global Medical Care industry.

( Industry Median: 8.00 vs. AMEX:HLTH: 13.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
AMEX:HLTH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -53.8  Med: 10.3 Max: 126.2
Current: 13.4
-53.8
126.2
3-Year EPS without NRI Growth Rate 26.00
AMEX:HLTH's 3-Year EPS without NRI Growth Rate is ranked higher than
79% of the 145 Companies
in the Global Medical Care industry.

( Industry Median: 7.50 vs. AMEX:HLTH: 26.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
AMEX:HLTH' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -78.9  Med: 26 Max: 223.8
Current: 26
-78.9
223.8
GuruFocus has detected 4 Warning Signs with Nobilis Health Corp $AMEX:HLTH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AMEX:HLTH's 30-Y Financials

Financials (Next Earnings Date: 2017-11-07 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

HLTH Guru Trades in Q2 2016

Chuck Royce 1,590,800 sh (+28.74%)
Jim Simons Sold Out
» More
Q3 2016

HLTH Guru Trades in Q3 2016

Jim Simons 33,500 sh (New)
Chuck Royce 1,515,800 sh (-4.71%)
» More
Q4 2016

HLTH Guru Trades in Q4 2016

Jim Simons Sold Out
Chuck Royce 1,465,800 sh (-3.30%)
» More
Q1 2017

HLTH Guru Trades in Q1 2017

Chuck Royce 1,464,000 sh (-0.12%)
» More
» Details

Insider Trades

Latest Guru Trades with HLTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621999    SIC: 8619
Compare:NYSE:QHC, NYSE:AAC, NAS:CATS, OTCPK:AMEH, NAS:JYNT, OTCPK:CCEL, OTCPK:FCHS, OTCPK:ADPTQ, OTCPK:BICX, OTCPK:MIHI, AMEX:AMS, TSXV:CXV, OTCPK:HPHW, AMEX:SSY, OTCPK:PFHO, TSXV:AHI, OTCPK:WNDM, OTCPK:LMNK, OTCPK:ATMS, OTCPK:SPIN » details
Traded in other countries:NHC.Canada, NH1.Germany,
Headquarter Location:USA
Nobilis Health Corp is a full-service healthcare development and management company, with 25 locations in seven states, including 4 hospitals, 10 ASCs and 11 clinics. In addition, it partners with another 38 facilities across the country.

Northstar Healthcare, Inc. partners with the physicians in the development and management of ambulatory surgery centres in the United States. It manages an ambulatory surgery centre in Dallas and two pain management clinics in Houston.

Top Ranked Articles about Nobilis Health Corp

Nobilis Health Announces Results of 2017 Annual General Meeting of Shareholders
Nobilis Health Corp. Appoints New Vice President of Marketing
Nobilis Health Corp. Announces First Quarter 2017 Earnings Release Date and Conference Call Details
Nobilis Expands Footprint to Galveston County With Acquisition of Surgery Center

HOUSTON, TX--(Marketwired - Sep 19, 2016) -  Nobilis Health Corp. (NYSE MKT: HLTH) (TSX: NHC) ("Nobilis" or the "Company") announced today that it has acquired an Ambulatory Surgery Center (ASC) in Dickinson, TX which will operate as a Hospital Outpatient Department (HOPD) of Nobilis' Bellaire Surgical Hospital. The new 8,387 square-foot facility has two operating suites, four pre-operative beds, and four recovery beds and will provide multispecialty services including those offered under Nobilis' six direct to consumer marketing brands. This ASC expands Nobilis's geographic reach into the southeast Houston Metro area, allowing it to reach doctors and patients currently unserved by its existing Houston-area facilities.  Nobilis Currently operates five other facilities in the Greater Houston Metropolitan area. The Greater Houston Metropolitan area is the fifth largest in the country and consists of 6.5 million people spread across 1,600 square miles and nine counties. The area includes the cities of Houston, The Woodlands, Katy, Clear Lake, Pearland, Sugar Land, Galveston, Dickinson, and many smaller communities. The new facility is located in the southeast region of the metropolitan area and will serve the communities of Clear Lake, Pearland and Galveston.  The transaction includes the lease of the facility location, the acquisition of necessary medical equipment and inventory for a nominal purchase price, the transfer of the ASC license and the execution of a campus management agreement through which Nobilis will manage the outpatient department. "This expansion taps into our ability to drive volume and revenue from our Sales and Marketing division, as seen from the success we've had in the Dallas, Plano, Phoenix, Scottsdale and Houston areas," said Kenneth Efird, President of Nobilis. "By adding this ASC we will be able to serve new patients and new physicians who are currently outside the reach of our existing Houston locations." About Nobilis Health Corp. Nobilis (www.NobilisHealth.com) is a full-service healthcare development and management company which currently owns or manages four surgical hospitals and five ASCs, partners with thirty-six additional facilities throughout the country, and markets six independent brands. Deploying a unique patient acquisition strategy driven by direct-to-consumer marketing, Nobilis is focused on a specified set of procedures that are performed at our centers by local physicians. Forward Looking Statements This press release contains certain forward-looking statements within the meaning of Canadian and United States securities laws, including the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts and may be identified by the use of words such as "may," "believe," "will," "expect," "project," "estimate," "anticipate," "plan" or "continue." These forward-looking statements are based on current plans and expectations and are subject to a number of risks, uncertainties and other factors which could significantly affect current plans and expectations and our future financial condition and results. These factors, which could cause actual results, performance and achievements to differ materially from those anticipated, include, but are not limited to our ability to successfully maintain effective internal controls over financial reporting; our ability to implement our business strategy, manage the growth in our business, and integrate acquired businesses; the risk of litigation and investigations, and liability claims for damages and other expenses not covered by insurance; the risk that payments from third-party payers, including government healthcare programs, may decrease or not increase as costs increase; adverse developments affecting the medical practices of our physician limited partners; our ability to maintain favorable relations with our physician limited partners; our ability to grow revenues by increasing case and procedure volume while maintaining profitability at the Nobilis Facilities; failure to timely or accurately bill for services; our ability to compete for physician partners, patients and strategic relationships; the risk of changes in patient volume and patient mix; the risk that laws and regulations that regulate payments for medical services made by government healthcare programs could cause our revenues to decrease; the risk that contracts are cancelled or not renewed or that we are not able to enter into additional contracts under terms that are acceptable to us; and the risk of potential decreases in our reimbursement rates. The foregoing are significant factors we think could cause our actual results to differ materially from expected results. However, there could be additional factors besides those listed herein that also could affect us in an adverse manner. We have not undertaken any obligation to publicly update or revise any forward-looking statements. All of our forward-looking statements speak only as of the date of the document in which they are made or, if a date is specified, as of such date. Subject to a mandatory requirements of applicable law, we disclaim any obligation or undertaking to provide any updates or revisions to any forward-looking statement to reflect any change in our expectations or any changes in events, conditions, circumstances or information on which the forward-looking statement is based. All subsequent written and oral forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by the foregoing factors and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2015, filed on March 15, 2016, as updated by other filings with the Securities and Exchange Commission.


Contact Information:

Kolin Ozonian

Vice President, Corporate Development

[email protected]

713-355-8614





Read more...

Ratios

vs
industry
vs
history
PE Ratio 15.91
HLTH's PE Ratio is ranked higher than
78% of the 201 Companies
in the Global Medical Care industry.

( Industry Median: 26.05 vs. HLTH: 15.91 )
Ranked among companies with meaningful PE Ratio only.
HLTH' s PE Ratio Range Over the Past 10 Years
Min: 2.99  Med: 13.9 Max: 77.19
Current: 15.91
2.99
77.19
PE Ratio without NRI 15.91
HLTH's PE Ratio without NRI is ranked higher than
81% of the 197 Companies
in the Global Medical Care industry.

( Industry Median: 26.57 vs. HLTH: 15.91 )
Ranked among companies with meaningful PE Ratio without NRI only.
HLTH' s PE Ratio without NRI Range Over the Past 10 Years
Min: 2.99  Med: 13.9 Max: 77.19
Current: 15.91
2.99
77.19
Price-to-Owner-Earnings 30.70
HLTH's Price-to-Owner-Earnings is ranked lower than
62% of the 106 Companies
in the Global Medical Care industry.

( Industry Median: 27.37 vs. HLTH: 30.70 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
HLTH' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 4.82  Med: 20 Max: 1120
Current: 30.7
4.82
1120
PB Ratio 0.96
HLTH's PB Ratio is ranked higher than
87% of the 242 Companies
in the Global Medical Care industry.

( Industry Median: 2.54 vs. HLTH: 0.96 )
Ranked among companies with meaningful PB Ratio only.
HLTH' s PB Ratio Range Over the Past 10 Years
Min: 0.64  Med: 2.67 Max: 12.83
Current: 0.96
0.64
12.83
PS Ratio 0.46
HLTH's PS Ratio is ranked higher than
88% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 1.69 vs. HLTH: 0.46 )
Ranked among companies with meaningful PS Ratio only.
HLTH' s PS Ratio Range Over the Past 10 Years
Min: 0.19  Med: 0.82 Max: 3.82
Current: 0.46
0.19
3.82
Price-to-Free-Cash-Flow 20.83
HLTH's Price-to-Free-Cash-Flow is ranked higher than
54% of the 116 Companies
in the Global Medical Care industry.

( Industry Median: 24.30 vs. HLTH: 20.83 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
HLTH' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 0.46  Med: 22.32 Max: 1833.33
Current: 20.83
0.46
1833.33
Price-to-Operating-Cash-Flow 9.72
HLTH's Price-to-Operating-Cash-Flow is ranked higher than
69% of the 167 Companies
in the Global Medical Care industry.

( Industry Median: 15.16 vs. HLTH: 9.72 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
HLTH' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 0.45  Med: 12.09 Max: 119.57
Current: 9.72
0.45
119.57
EV-to-EBIT 9.25
HLTH's EV-to-EBIT is ranked higher than
89% of the 208 Companies
in the Global Medical Care industry.

( Industry Median: 20.05 vs. HLTH: 9.25 )
Ranked among companies with meaningful EV-to-EBIT only.
HLTH' s EV-to-EBIT Range Over the Past 10 Years
Min: -9.9  Med: 5.4 Max: 30.1
Current: 9.25
-9.9
30.1
EV-to-EBITDA 6.51
HLTH's EV-to-EBITDA is ranked higher than
90% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 15.41 vs. HLTH: 6.51 )
Ranked among companies with meaningful EV-to-EBITDA only.
HLTH' s EV-to-EBITDA Range Over the Past 10 Years
Min: -28.5  Med: 5.2 Max: 378.2
Current: 6.51
-28.5
378.2
Current Ratio 2.28
HLTH's Current Ratio is ranked higher than
77% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 1.32 vs. HLTH: 2.28 )
Ranked among companies with meaningful Current Ratio only.
HLTH' s Current Ratio Range Over the Past 10 Years
Min: 0.56  Med: 2.64 Max: 6.55
Current: 2.28
0.56
6.55
Quick Ratio 2.22
HLTH's Quick Ratio is ranked higher than
78% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 1.25 vs. HLTH: 2.22 )
Ranked among companies with meaningful Quick Ratio only.
HLTH' s Quick Ratio Range Over the Past 10 Years
Min: 0.53  Med: 2.47 Max: 6.08
Current: 2.22
0.53
6.08
Days Inventory 68.14
HLTH's Days Inventory is ranked lower than
87% of the 198 Companies
in the Global Medical Care industry.

( Industry Median: 15.65 vs. HLTH: 68.14 )
Ranked among companies with meaningful Days Inventory only.
HLTH' s Days Inventory Range Over the Past 10 Years
Min: 18.45  Med: 42.57 Max: 1996.6
Current: 68.14
18.45
1996.6
Days Sales Outstanding 123.85
HLTH's Days Sales Outstanding is ranked lower than
94% of the 215 Companies
in the Global Medical Care industry.

( Industry Median: 40.40 vs. HLTH: 123.85 )
Ranked among companies with meaningful Days Sales Outstanding only.
HLTH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.52  Med: 84.27 Max: 175.75
Current: 123.85
44.52
175.75
Days Payable 277.27
HLTH's Days Payable is ranked higher than
91% of the 160 Companies
in the Global Medical Care industry.

( Industry Median: 44.51 vs. HLTH: 277.27 )
Ranked among companies with meaningful Days Payable only.
HLTH' s Days Payable Range Over the Past 10 Years
Min: 34.18  Med: 53.75 Max: 19118.01
Current: 277.27
34.18
19118.01

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -28.30
HLTH's 3-Year Average Share Buyback Ratio is ranked lower than
88% of the 141 Companies
in the Global Medical Care industry.

( Industry Median: -2.20 vs. HLTH: -28.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
HLTH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -37.4  Med: -26 Max: 27.4
Current: -28.3
-37.4
27.4

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 2.73
HLTH's Price-to-Tangible-Book is ranked higher than
59% of the 187 Companies
in the Global Medical Care industry.

( Industry Median: 3.75 vs. HLTH: 2.73 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
HLTH' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 1.69  Med: 5.08 Max: 190
Current: 2.73
1.69
190
Price-to-Intrinsic-Value-Projected-FCF 0.83
HLTH's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
84% of the 97 Companies
in the Global Medical Care industry.

( Industry Median: 1.97 vs. HLTH: 0.83 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
HLTH' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.05  Med: 0.3 Max: 5.11
Current: 0.83
0.05
5.11
Price-to-Median-PS-Value 0.56
HLTH's Price-to-Median-PS-Value is ranked higher than
90% of the 226 Companies
in the Global Medical Care industry.

( Industry Median: 1.10 vs. HLTH: 0.56 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
HLTH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 0.91 Max: 3.37
Current: 0.56
0.23
3.37
Price-to-Graham-Number 1.39
HLTH's Price-to-Graham-Number is ranked higher than
74% of the 138 Companies
in the Global Medical Care industry.

( Industry Median: 2.41 vs. HLTH: 1.39 )
Ranked among companies with meaningful Price-to-Graham-Number only.
HLTH' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.52  Med: 1.29 Max: 6.29
Current: 1.39
0.52
6.29
Earnings Yield (Greenblatt) % 10.81
HLTH's Earnings Yield (Greenblatt) % is ranked higher than
92% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 3.84 vs. HLTH: 10.81 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
HLTH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -114.9  Med: 12.5 Max: 91.5
Current: 10.81
-114.9
91.5

More Statistics

Revenue (TTM) (Mil) $302.77
EPS (TTM) $ 0.11
Beta-0.42
Short Percentage of Float9.48%
52-Week Range $1.10 - 3.86
Shares Outstanding (Mil)77.80

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 346 348 330
EPS ($) 0.39 0.38 0.41
EPS without NRI ($) 0.39 0.38 0.41
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for AMEX:HLTH

Headlines

Articles On GuruFocus.com
Nobilis Health Announces Results of 2017 Annual General Meeting of Shareholders Jun 12 2017 
Nobilis Health Corp. Appoints New Vice President of Marketing Jun 08 2017 
Nobilis Health Corp. Announces First Quarter 2017 Earnings Release Date and Conference Call Details Apr 26 2017 
Nobilis Expands Footprint to Galveston County With Acquisition of Surgery Center Sep 19 2016 
Nobilis Health Announces Results of 2016 Annual General Meeting of Shareholders Jun 28 2016 
Nobilis Announces Board Nominations for June 28th Shareholder Meeting May 26 2016 
Nobilis Health Corp. Announces Advance Notice Policy May 25 2016 
Nobilis to Participate in the 13th Annual Craig-Hallum Institutional Investor Conference May 23 2016 
Nobilis Health Corp. Appoints Chief Accounting Officer May 16 2016 
Nobilis Financial Update May 12 2016 

More From Other Websites
Top Ranked Growth Stocks to Buy for July 17th Jul 17 2017
The Zacks Analyst Blog Highlights: Nobilis Health, Extended Stay America, SYNNEX, Citizens Financial... Jul 11 2017
Top Ranked Value Stocks to Buy for July 10th Jul 10 2017
Advisory Board (ABCO) in Focus: Stock Moves 5.4% Higher Jul 10 2017
US Job Market Roars Back to Life: Top 5 Gainers Jul 10 2017
5 of the Best Stocks Under $10 for 2017 Jul 05 2017
Top Ranked Growth Stocks to Buy for July 3rd Jul 03 2017
ETFs with exposure to Nobilis Health Corp. : June 30, 2017 Jun 30 2017
Nobilis Health Corp. :HLTH-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Jun 16 2017
Top Ranked Growth Stocks to Buy for June 14th Jun 14 2017
Top 10 Stocks Under $20 Jun 13 2017
Nobilis Health Announces Results of 2017 Annual General Meeting of Shareholders Jun 12 2017
Zacks.com featured highlights: Tailored Brands, CAI International, Nobilis Health, Walker & Dunlop... Jun 12 2017
5 Magical Value Picks Based on Discounted PEG Jun 09 2017
Nobilis Health Corp. Appoints New Vice President of Marketing Jun 08 2017
Tenet Healthcare Prices New Notes to Repay Existing Debts Jun 06 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}